Cargando…

How personality influences health outcomes and quality of life in adult patients with cystic fibrosis

BACKGROUND: The present study evaluates personality traits in adult patients with cystic fibrosis (CF) and correlates these results with health-related quality of life (HRQoL) and other clinical parameters indicative of disease severity. METHODS: Seventy adults completed the Cystic Fibrosis Question...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niehammer, Ute, Straßburg, Svenja, Sutharsan, Sivagurunathan, Taube, Christian, Welsner, Matthias, Stehling, Florian, Hirtz, Raphael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233905/ https://www.ncbi.nlm.nih.gov/pubmed/37264349 http://dx.doi.org/10.1186/s12890-023-02463-y

Ejemplares similares

Cough suppression and HRQoL in adult people with cystic fibrosis: an unexplored correlation
por: Niehammer, Ute, et al.
Publicado: (2022)

Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis
por: Olivier, Margarete, et al.
Publicado: (2023)

Obstructive sleep apnea and nocturnal hypoxemia in adult patients with cystic fibrosis
por: Welsner, Matthias, et al.
Publicado: (2022)

Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T – a case report
por: Welsner, Matthias, et al.
Publicado: (2019)

Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system
por: Straßburg, Svenja, et al.
Publicado: (2022)

Changes in Clinical Markers During A Short-Term Transfer Program of Adult Cystic Fibrosis Patients from Pediatric to Adult Care
por: Welsner, Matthias, et al.
Publicado: (2019)

Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy
por: Westhölter, Dirk, et al.
Publicado: (2023)

Trainability of Health-Related and Motor Performance Fitness in Adults with Cystic Fibrosis within a 12-Month Partially Supervised Exercise Program
por: Welsner, Matthias, et al.
Publicado: (2021)

Barriers for Sports and Exercise Participation and Corresponding Barrier Management in Cystic Fibrosis
por: Dillenhoefer, Stefanie, et al.
Publicado: (2022)

Association between habitual physical activity (HPA) and sleep quality in patients with cystic fibrosis
por: Dietz-Terjung, Sarah, et al.
Publicado: (2020)

Effects of a Long-Term Monitored Exercise Program on Aerobic Fitness in a Small Group of Children with Cystic Fibrosis
por: Gruber, Wolfgang, et al.
Publicado: (2022)

Association between habitual physical activity (HPA) and sleep quality in patients with cystic fibrosis
por: Dietz-Terjung, Sarah, et al.
Publicado: (2020)

Long-Term Follow-Up of Health-Related Quality of Life and Short-Term Intervention with CFTR Modulator Therapy in Adults with Cystic Fibrosis: Evaluation of Changes over Several Years with or without 33 Weeks of CFTR Modulator Therapy
por: Gruber, Wolfgang, et al.
Publicado: (2023)

Species-Specific Interferon-Gamma Release Assay for the Diagnosis of Mycobacterium abscessus Complex Infection
por: Steindor, Mathis, et al.
Publicado: (2021)

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry
por: Sutharsan, Sivagurunathan, et al.
Publicado: (2023)

Coil embolisation for massive haemoptysis in cystic fibrosis
por: Dohna, Martha, et al.
Publicado: (2021)

Bronchial artery diameter in massive hemoptysis in cystic fibrosis
por: Dohna, Martha, et al.
Publicado: (2022)

An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa
por: Sutharsan, Sivagurunathan, et al.
Publicado: (2020)

A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF
por: Thee, Stephanie, et al.
Publicado: (2021)

Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study
por: Goss, Christopher H., et al.
Publicado: (2022)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
por: Stehling, Florian, et al.
Publicado: (2017)

Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus
por: Junge, Sibylle, et al.
Publicado: (2016)

New Developments in Cystic Fibrosis Airway Inflammation
por: Palaniyar, Nades, et al.
Publicado: (2015)

Immunomodulation in Cystic Fibrosis: Why and How?
por: Giacalone, Vincent D., et al.
Publicado: (2020)

Increased Safety Behavior and COVID-19-Related Fear in Adults with Cystic Fibrosis during the Pandemic
por: Benecke, Anke-Verena, et al.
Publicado: (2022)

Bacteraemia and fungaemia in cystic fibrosis patients with febrile pulmonary exacerbation: a prospective observational study
por: Grosse-Onnebrink, Joerg, et al.
Publicado: (2017)

Personalized or Precision Medicine? The Example of Cystic Fibrosis
por: Marson, Fernando A. L., et al.
Publicado: (2017)

Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 Pneumonia
por: Kattner, Simone, et al.
Publicado: (2023)

How are the ancient cystic fibrosis patients? Cystic fibrosis diagnosed over 60 years-old
por: Prados, C., et al.
Publicado: (2017)

The influence of IFITM3 polymorphisms on susceptibility to SARS-CoV-2 infection and severity of COVID-19
por: Schönfelder, Kristina, et al.
Publicado: (2021)

Biofilm infection of a central venous port-catheter caused by Mycobacterium avium complex in an immunocompetent child with cystic fibrosis
por: Kavvalou, Alexandra, et al.
Publicado: (2022)

Qulaity of Life in Cystic Fibrosis Children
por: Kianifar, Hamid-Reza, et al.
Publicado: (2013)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
por: Berges, Julian, et al.
Publicado: (2023)

Mycobacterium Simiae Infection in a Person With Cystic Fibrosis
por: FitzMaurice, Thomas S, et al.
Publicado: (2020)

The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
por: Shemie, Genevieve, et al.
Publicado: (2021)

Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis
por: Harwood, Kiera H., et al.
Publicado: (2021)

Cystic Fibrosis Transmembrane Conductance Regulator Genotype, Not Circulating Catecholamines, Influences Cardiovascular Function in Patients with Cystic Fibrosis
por: Bisch, Alexander L, et al.
Publicado: (2019)

Factors influencing quality of life and disease severity in Hungarian children and young adults with cystic fibrosis
por: Bodnar, Reka, et al.
Publicado: (2014)

How Can We Target Pulmonary Inflammation in Cystic Fibrosis?
por: Greene, Catherine M.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8fm55stdhpvmaos07otn6qrn86